Edwards Lifesciences (EW)
NYSE:EW
Want to see EW full AI Analyst Report?
EW Stock Chart & Stats
$80.99
$0.80(1.09%)
At close: 4:00 PM EST
$80.99
$0.80(1.09%)
Day’s Range― - ―
52-Week Range$72.30 - $87.89
Previous CloseN/A
Volume821.68K
Average Volume (3M)4.57M
Market Cap
$48.42B
Enterprise Value$46.18B
Total Cash (Recent Filing)$4.23B
Total Debt (Recent Filing)$705.40M
Price to Earnings (P/E)30.5
Beta0.61
Next Earnings
Jul 23, 2026EPS Estimate
0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.78
Shares Outstanding576,541,700
10 Day Avg. Volume5,051,131
30 Day Avg. Volume4,565,397
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)4.82
Price to Sales (P/S)8.22
P/FCF Ratio37.34
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue7.61
Enterprise Value/Gross Profit9.75
Enterprise Value/Ebitda33.19
Forecast
1Y Price Target
$96.74Price Target Upside19.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
EPS Forecast (FY)3.01
Revenue Forecast (FY)$6.75B
Bulls Say, Bears Say
Bulls Say
Clinical Trial OutcomesRandomized and extended clinical data for the EVOQUE transcatheter tricuspid valve replacement demonstrated durable near-elimination of tricuspid regurgitation, a mortality benefit versus medical therapy, and sustained quality-of-life gains, supporting broader clinical adoption.
Competitor Setbacks And Market OpportunityLeadership departures and operational issues at a rival's TAVR program, along with reported share erosion at high-volume centers, create a clear market-share opportunity for Edwards in transcatheter aortic valve replacement.
Revenue And Guidance StrengthQuarterly sales beat expectations driven by TAVR and transcatheter mitral and tricuspid therapies, and management reiterated confidence in the full-year outlook, reinforcing analyst expectations for sustained growth.
Bears Say
Clinical Data Interpretation RiskHigh crossover rates left few non-crossover controls and an intention-to-treat analysis did not achieve statistical significance on the composite endpoint, complicating efficacy and safety interpretation for some clinicians.
New Competitive ThreatA major device company initiating development of a balloon-expandable TAVR product increases competitive pressure and could limit Edwards' long-term market upside.
Profitability Risk From InvestmentsElevated spending on patient-access programs and awareness initiatives, combined with a higher tax rate, pressured adjusted operating margin and contributed to an earnings-per-share shortfall versus analyst expectations.
Edwards Lifesciences News
EW FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Edwards Lifesciences lowest stock price was $72.30 and its highest was $87.89 in the past 12 months.
What is Edwards Lifesciences’s market cap?
Edwards Lifesciences’s market cap is $48.42B.
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Jul 23, 2026 which is in 80 days.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Apr 23, 2026. The company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.729 by $0.051.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is 0.74.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 576,541,700 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of $0.78 in its last earnings report, beating expectations of $0.729. Following the earnings report the stock price went up 5.557%.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Currently, no hedge funds are holding shares in EW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edwards Lifesciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$96.74 (19.44% Upside)
$96.74 (19.44% Upside)
Blogger Sentiment
Bullish
EW Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 3.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Company Description
Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
EW Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a broadly positive outlook: the company delivered strong top‑line growth (Q4 +11.6%, FY +10.7%), robust TAVR and TMTT momentum, and reiterated confident 2026 guidance (8%–10% sales growth; EPS $2.90–$3.05). Key positives include compelling long‑term clinical evidence, successful product launches (SAPIEN M3, NextGen PASCAL), margin discipline and a healthy balance sheet. Near‑term headwinds are primarily deliberate investments in patient access and field resources (driving higher SG&A), one‑time GAAP charges (GennaValve/litigation), an elevated tax rate in the quarter, and distributor inventory adjustments that modestly impacted surgical sales. Management frames the incremental spending as strategic and expects margin expansion over time. Overall, the positive operational and strategic catalysts outweigh the one‑time and timing‑related negatives.View all EW earnings summariesEW Net sales Breakdown
73.96% Transcatheter Aortic Valve Replacement
9.07% Transcatheter Mitral and Tricuspid Therapies
16.96% Surgical Structural Heart
EW Stock 12 Month Forecast
Average Price Target
$96.74
▲(19.44% Upside)
Technical Analysis
Ownership Overview
0.21% Insiders
25.12% Mutual Funds
5.85% Other Institutional Investors
43.60% Public Companies and
Individual Investors